ACL : Live and Let Die?

I love a good Bond film and my favorite is, without hesitation, “Live and Let Die”. Charismatic villains, gorgeous but complex “starlets”, and Roger Moore at his gorgonzola-best. McCartney’s awesome sound track is surprisingly glam rock for the era, reminding us that after all the optimism and hope of youth – “live and let live” – is…

Alchemia has a VAST problem

It was only two years ago that Alchemia (ASX : ACL) informed us, with great fanfare and celebration, of the collaboration with AstraZeneca involving the VAST program. It was a pretty exciting story, especially for an early-stage platform technology. R&D cost offsets, potential milestones/royalties. Big potential, heady stuff. Two years on, we have seen the company’s fortunes…

ACL : Erratum (Mr. Ken Poutakidis)

By way of follow-up to my previous post on Alchemia (ASX : ACL), I have been informed that my implied statement that Mr Ken Poutakidis, who recently joined the struggling board of ACL, was previously a director of Phosphagenics (ASX : POH) is in fact incorrect. I made a determination on the basis of reasonable information that was…

NRT, ANP, PYC, ACL, OBJ : A Week in Contrast

Last week was a pretty exciting week in Australian life sciences. Quite a bit happened, in fact I struggled to stay on top of it while being on vacation. We’ve seen a couple of good things happen, like PharmAxis, Sirtex recovery, etc. that are real bright spots on the Aussie biotech landscape. We’ve seen some…

Alchemia : Lead into Gold?

The last two days have marked fairly significant changes of ownership position in Alchemia (ASX : ACL), suggesting a very interesting turning point in the company. I particularly note that Sandon Capital, an activist fund, now seems to be the 3rd largest shareholder in ACL and is starting to accumulate some reasonably impacting voting rights. In my opinion,…